Opening book details…
Can I read Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial on EtoBox?
Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial by Joris B.W. Elbers; Abrahim Al-Mamgani; Margot E.T. Tesseslaar; Michiel W.M. van den Brekel; Charlotte A.H. Lange; Jacqueline E. van der Wal; Marcel Verheij; Charlotte L. Zuur; Jan Paul de Boer is a Medicine article available to read on EtoBox.
What is Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial about?
## Background and purpose: Radiotherapy (rt) with cetuximab is an alternative for advanced-stage head and neck squamous cell carcinoma (hnscc) patients who are unfit for cisplatin treatment. as 5-year overall survival is below 50%, it is of interest to test pd-l1 immune checkpoint blockade (avelumab) with cetuximab-rt in the curative setting. ## Materials and methods: Phase-i feasibility trial (planned n = 10, nct02938273) of conventional cetuximab-rt with avelumab (concurrent 10 mg/kg q2w + 4 months maintenance) for advanced-stage hnscc patients unfit for cisplatin treatment. ## Results: One of ten included patients experienced grade 2 cetuximab-related infusion reaction and withdrew from the study before avelumab was administered. one patient discontinued treatment after 2 courses of avelumab and 12×2gy rt for personal reasons. in 2/8 remaining patients, avelumab was stopped after 4 and 8 courses because of toxicity and tumor progression, respectively. there was no grade 4-5 toxicity. grade 3 immune-related toxicity was manageable and occurred in 4 patients. one patient was treated with topical steroids for grade 3 maculopapular rash and 3 patients received high-dose prednisone f
Who reads Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Joris B.W. Elbers; Abrahim Al-Mamgani; Margot E.T. Tesseslaar; Michiel W.M. van den Brekel; Charlotte A.H. Lange; Jacqueline E. van der Wal; Marcel Verheij; Charlotte L. Zuur; Jan Paul de Boer
- Published
- 2019
- Language
- EN
- Field
- Medicine (Health Sciences)